Lv1
30 积分 2025-11-09 加入
KRAS: From undruggable to a druggable Cancer Target
1天前
待确认
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
1天前
已完结
Targeting KRASG12C Mutation: Development of effective strategies to overcome drug resistance and limited efficacy
1天前
已完结
Efficacy and safety of anti-PD-1 versus anti-PD-L1 in perioperative immunotherapy
1天前
已完结
Mito-Specific “Trojan Horse” Nanotherapy: Synergistic Antitumor Immunotherapy via Dual Modulation Mitochondrial Metabolism and Glycolysis
1个月前
已完结
皖公网安备34019202002308
